The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice
Open accessAbstract
The design of the mRNA vaccine involves the selection of in vitro transcription (IVT) systems and nonviral delivery vectors. This study aimed to verify the effect of 5’ and 3’ untranslated region (UTR) sequences on the translation efficiency of mRNA. Three modes of IVT-mRNA systems (IVT-mRNA-n1/n2/n3) with diverse UTRs were constructed, and EGFP (enhanced green fluorescent protein) and HA (hemagglutinin) gene of H3N2 influenza virus were introduced into each of them. The results showed that the mode of 5’ and 3’ UTRs originating from human β-globulin was better than the mode of UTRs from human α-globulin, and the n3 mode was the best. mEGFP-n3, mH3HA-n3, and mLuciferease-n3 were prepared to compare the effect of cationic lipid nanoparticle (LNP) with that of mannose-conjugated LNP (LNP-Man) on the efficiency of gene delivery. The results showed that the effect of LNP-Man was better than that of LNP both in vitro and in vivo. Choosing appropriate ligands might help in vaccine design. After selecting the IVT-mRNA-n3 system and delivery vectors, mRNA vaccines were constructed against the H1N1 influenza virus, and C57BL/6 mice were immunized through intranasal administration. The results showed that mRNA vaccines could elicit both humoral and cellular immune responses and completely protect mice from the tenfold LD50 H1N1 influenza virus challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lipid nanoparticle–mRNA vaccines are also being investigated as influenza vaccines29,41,156,157,159,184,189–191, with some formulations in clinical trials (Table 1).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,741
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
The evolution of seasonal influenza viruses
Petrova, V. N., & Russell, C. A. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.118 · Cited by 889
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
The human antibody response to influenza A virus infection and vaccination
Krammer, F. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0143-6 · Cited by 819
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Nanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 271
Formulation and Delivery Technologies for mRNA Vaccines
Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 228
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
Wang, B., Pei, J., Xu, S., Liu, J., & Yu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1246682 · Cited by 131
Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications
Leong, K. Y., Tham, S. K., & Poh, C. L. (2025) · Virology Journal · doi:10.1186/s12985-025-02645-6 · Cited by 139
Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024) · Vaccines · doi:10.3390/vaccines12020186 · Cited by 137
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 99
Mucosal vaccine delivery: A focus on the breakthrough of specific barriers
Huang, M., Zhang, M., Zhu, H., Du, X., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.002 · Cited by 96
Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 100
Sun, W., He, L., Zhang, H., Tian, X., Bai, Z., Sun, L., Yang, L., Jia, X., Bi, Y., Luo, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00750-w · Cited by 83
Self-citationNanomaterials in cancer: Reviewing the combination of hyperthermia and triggered chemotherapy
Ribeiro, T. P., Moreira, J. A., Monteiro, F. J., & Laranjeira, M. S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.045 · Cited by 90
Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 80
Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 80
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 76
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 76
Influenza and Universal Vaccine Research in China
Li, J., Zhang, Y., Zhang, X., & Liu, L. (2022) · Viruses · doi:10.3390/v15010116 · Cited by 74
Hameed, S. A., Paul, S., Dellosa, G. K. Y., Jaraquemada, D., & Bello, M. B. (2022) · npj Vaccines · doi:10.1038/s41541-022-00485-x · Cited by 65
van de Ven, K., Lanfermeijer, J., van Dijken, H., Muramatsu, H., de Melo, C. V. B., Lenz, S., Peters, F., Beattie, M. B., Lin, P. J. C., Ferreira, J. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9937 · Cited by 66
Maharjan, R., Hada, S., Lee, J., Han, H.-K., Kim, K. H., Seo, H. J., Foged, C., & Jeong, S. H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123012 · Cited by 66
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
Matarazzo, L., & Bettencourt, P. J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172691 · Cited by 68
Recent Advances in the Noninvasive Delivery of mRNA
Qin, M., Du, G., & Sun, X. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00493 · Cited by 62
Xiong, F., Zhang, C., Shang, B., Zheng, M., Wang, Q., Ding, Y., Luo, J., & Li, X. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2256422 · Cited by 60
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges
Bai, Z., Wan, D., Lan, T., Hong, W., Dong, H., Wei, Y., & Wei, X. (2024) · ACS Nano · doi:10.1021/acsnano.3c10797 · Cited by 58
Integrated mRNA sequence optimization using deep learning
Gong, H., Wen, J., Luo, R., Feng, Y., Guo, J., Fu, H., & Zhou, X. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad001 · Cited by 57
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases
Jiao, L., Sun, Z., Sun, Z., Liu, J., Deng, G., & Wang, X. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1349077 · Cited by 48
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
Карпенко, Л. И., Рудометов, А. П., Sharabrin, S. V., Щербаков, Д. Н., Borgoyakova, M. B., Bazhan, S. I., Volosnikova, E. A., Борисовна, Р. Н., Orlova, L. A., Pyshnaya, I. A., et al. (2021) · Vaccines · doi:10.3390/vaccines9020076 · Cited by 40
Zhu, W. S., Wei, L., Dong, C., Wang, Y., Kim, J. H., Ma, Y., Gonzalez, G. X., & Wang, B. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.024 · Cited by 38
Nanocarrier vaccine therapeutics for global infectious and chronic diseases
Simnani, F. Z., Singh, D., Patel, P., Choudhury, A., Sinha, A., Nandi, A., Samal, S. K., Verma, S. K., & Panda, P. K. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.008 · Cited by 38
Li, Y., Wang, F., Yang, J., Han, Z., Chen, L., Jiang, W., Zhou, H., Li, T., Tang, Z., Deng, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64894-x · Cited by 37
Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
Provine, N. M., & Klenerman, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202250022 · Cited by 37
Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
Kackos, C. M., DeBeauchamp, J., Davitt, C. J. H., Lonzarić, J., Sealy, R. E., Hurwitz, J. L., Samsa, M. M., & Webby, R. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00752-5 · Cited by 38
Meany, E. L., Klich, J. H., Jons, C. K., Mao, T., Chaudhary, N., Utz, A., Baillet, J., Song, Y. E., Saouaf, O. M., Ou, B. S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2631 · Cited by 37
Cationic Nanostructures for Vaccines Design
Carmona‐Ribeiro, A. M., & Pérez-Betancourt, Y. (2020) · Biomimetics · doi:10.3390/biomimetics5030032 · Cited by 33
Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
Aldon, Y., McKay, P. F., Herrero, J. M., Vogel, A. B., Lévai, R. F., Maisonnasse, P., Dereuddre‐Bosquet, N., Haas, H., Fábián, K., Grand, R. L., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.008 · Cited by 34
Mucosal vaccine development for respiratory viral infections
Lin, Y., Hu, Z., Fu, Y., & Peng, H. (2023) · hLife · doi:10.1016/j.hlife.2023.12.005 · Cited by 33
Promising Adjuvants and Platforms for Influenza Vaccine Development
Zhu, W., Dong, C., Wei, L., & Wang, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010068 · Cited by 34
Advances in mRNA and other vaccines against MERS-CoV
Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 36
Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines
Bolhassani, A. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00624-8 · Cited by 36
Muco‐Penetrating Lipid Nanoparticles Having a Liquid Core for Enhanced Intranasal mRNA Delivery
Maniyamgama, N., Bae, K. H., Chang, Z. W., Lee, J., Ang, M. J. Y., Tan, Y. J., Ng, L. F. P., Rénia, L., White, K. P., & Yang, Y. Y. (2025) · Advanced Science · doi:10.1002/advs.202407383 · Cited by 33
The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges
Zhang, F., Zhou, Y., & Ding, J. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00368-y · Cited by 30
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 29
Zhuang, X., Chen, L., Yang, S., Xia, S., Xu, Z., Zhang, T., Zeng, B., Yu, T., Yu, N., Wang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836274 · Cited by 27
Self-citationDeveloping mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 33
Xu, Z. C., Xiao, Z.-X., Wang, J., Qiu, H.-W., Cao, F., Zhang, S., Xu, Y.-D., Lei, H., Xia, H., He, Y.-R., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2373526 · Cited by 25
Shahrear, S., & Islam, A. B. M. M. K. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10515-4 · Cited by 24
Cao, L., Yu, Y.-F., Li, Z., Zhong, N., Wang, G.-R., Xiao, Y., Liu, B., Wu, Q., Feng, C., & Bu, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02590-6 · Cited by 28
Chen, T., Zhu, S., Wei, N., Zhao, Z., Niu, J., Si, Y., Cao, S., & Ye, J. (2022) · Viruses · doi:10.3390/v14061121 · Cited by 23
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines
Xiao, W., Wang, F., Gu, Y., He, X., Fan, N., Zheng, Q., Qin, S., He, Z., Wei, Y., & Song, X. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108755 · Cited by 22
Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles
Higuchi, A., Sung, T., Wang, T., Ling, Q., Kumar, S. S., Hsu, S.-T., & Umezawa, A. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2106490 · Cited by 21
mRNA Vaccine Platform: mRNA Production and Delivery
Litvinova, V. R., Рудометов, А. П., Карпенко, Л. И., & Ilyichev, A. A. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020152 · Cited by 26
Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice
Lu, C., Li, Y., Chen, R., Hu, X., Leng, Q., Song, X., Lin, X., Ye, J., Wang, J., Li, J., et al. (2024) · Viruses · doi:10.3390/v16020211 · Cited by 19
Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
Hauguel, T., Sharma, A. M., Mastrocola, E., Lowry, S., Maddur, M. S., Hu, C. H., Rajput, S., Vitsky, A., Choudhary, S., Manickam, B., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00980-3 · Cited by 21
Chicken Secondary Lymphoid Tissues—Structure and Relevance in Immunological Research
Ceccopieri, C., & Madej, J. P. (2024) · Animals · doi:10.3390/ani14162439 · Cited by 19
Cao, M., Li, Y., Song, X., Lu, Z., Zhai, H., Qiu, H., & Sun, Y. (2025) · Journal of Virology · doi:10.1128/jvi.00997-25 · Cited by 24
Subtype H3N2 Influenza A Viruses: An Unmet Challenge in the Western Pacific
Kang, M., Zanin, M., & Wong, S. (2022) · Vaccines · doi:10.3390/vaccines10010112 · Cited by 19
mRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 27
Ma, N., Xia, Z.-W., Zhang, Z., Nian, X., Li, X.-D., Gong, Z., Zhang, G., Yang, L., Zhou, R., Zhang, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2202278 · Cited by 18
mRNA vaccine development and applications: A special focus on tumors (Review)
Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., et al. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5669 · Cited by 17
Synthesis and characterization of ZnO and CuO coatings for antibacterial and antiviral applications
Mannai, Z., Bousslama, W., Karkouch, I., Bouslama, L., Khlifi, K., Aouadi, K., & Nouira, F. (2024) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2024.130071 · Cited by 16
Shahrear, S., & Islam, A. B. M. M. K. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105098 · Cited by 16
STxB as an Antigen Delivery Tool for Mucosal Vaccination
Tartour, É., & Johannes, L. (2022) · Toxins · doi:10.3390/toxins14030202 · Cited by 15
Di, Y., Zhang, C., Ren, Z., Jiang, R., Tang, J., Yang, S., Wang, Z., Yu, T., Zhang, T., Yu, Z., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1483720 · Cited by 17
Self-citationRespiratory delivered vaccines: Current status and perspectives in rational formulation design
Wu, L., Xu, W., Jiang, H., Yang, M., & Cun, D. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.026 · Cited by 19
Homaeigohar, S., Liu, Q., & Kordbacheh, D. (2021) · Polymers · doi:10.3390/polym13162833 · Cited by 15
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Aroffu, M., Manca, M. L., Pedraz, J. L., & Manconi, M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2288856 · Cited by 15
UTR-Insight: integrating deep learning for efficient 5′ UTR discovery and design
Pan, S., Wang, H., Zhang, H., Tang, Z., Xu, L., Yan, Z., & Hu, Y. (2025) · BMC Genomics · doi:10.1186/s12864-025-11269-7 · Cited by 15
Self-citationInfluenza vaccines: where we are, where we are going.
Khalil, N., & Bernstein, D. I. (2022) · PubMed · doi:10.1097/mop.0000000000001103 · Cited by 9
Colaço, M., Cruz, M. T., de Almeida, L. P., & Borges, O. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101308 · Cited by 12
Progress in antisenescence biomaterials for improved osteoarthritis therapy
Ge, Y.-S., Ding, J.-Y., Shen, J., Meng, T.-T., Huang, C.-M., Li, W.-Y., Zhao, M.-J., Yin, J.-L., Zhai, Y.-Q., Wang, X., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.044 · Cited by 13
Hendy, D. A., Ma, Y., Dixon, T. A., Murphy, C. T., Pena, E. S., Carlock, M. A., Ross, T. M., Bachelder, E. M., Ainslie, K. M., & Fenton, O. S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.007 · Cited by 12
Tsukamoto, K., Yamashita, A., Maeki, M., Tokeshi, M., Imai, H., Fukao, A., Fujiwara, T., Okudera, K., Mizuki, N., Okuda, K., et al. (2024) · Vaccines · doi:10.3390/vaccines12111239 · Cited by 11
Engineer RNA‐Protein Nanowires as Light‐Responsive Biomaterials
Younas, T., Liu, C., Struwe, W. B., Kukura, P., & He, L. (2023) · Small · doi:10.1002/smll.202206513 · Cited by 11
Flu RNA Vaccine: A Game Changer?
Meurens, F. (2020) · Vaccines · doi:10.3390/vaccines8040760 · Cited by 9
Guo, J., Ma, S., Mai, Y., Gao, T., Song, Z., & Yang, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109254 · Cited by 10
Shadid, A., Rich, H. E., DeVaughn, H., Domozhirov, A. Y., Doursout, M., Mills, T., Eckel‐Mahan, K. L., Karmouty‐Quintana, H., Restrepo, M. I., & Shivshankar, P. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1479801 · Cited by 9
The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines
Lu, H., Xiao, J., Song, J., Song, Y., Li, H., Ren, H., Li, J., Cong, R., Li, H., Fang, Y., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70201 · Cited by 9
Self-citationYahyaei, S., Abdoli, A., Jamali, A., Teimoori, A., Arefian, E., Eftekhari, Z., & Jamur, P. (2025) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70093 · Cited by 9
La nueva generación de vacunas de ARN mensajero (ARNm) frente a la gripe
Reina, J. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.07.009 · Cited by 11
Identification of a Novel Interferon Lambda Splice Variant in Chickens
Chen, J., Li, P., Zou, W., Jiang, Y., Li, L., Hao, P., Gao, Z., Qu, Q., Pang, Z., Zhuang, X., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01743-22 · Cited by 9
Self-citationThe new generation of messenger RNA (mRNA) vaccines against influenza
Reina, J. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.07.006 · Cited by 10
mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
Kackos, C. M., Surman, S. L., Jones, B. G., Sealy, R. E., Jeevan, T., Davitt, C. J. H., Pustylnikov, S., Darling, T. L., Boon, A. C. M., Hurwitz, J. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04240-22 · Cited by 9
Emerging Cationic Nanovaccines
Carmona‐Ribeiro, A. M., & Pérez-Betancourt, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111362 · Cited by 8
de Moura, I. A., Silva, A. J. D., de Macêdo, L. S., de Melo, K. M. T. B., Leal, L. R. S., Espinoza, B. C. F., Invenção, M. D. C. V., de Pinho, S. S., & de Freitas, A. C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050640 · Cited by 10
Harnessing the Potential of mRNA Vaccines Against Infectious Diseases
Rezk, N., & McClean, S. (2025) · Microbial Biotechnology · doi:10.1111/1751-7915.70212 · Cited by 10
Alrumaihi, F., Alromaihi, R. A., Kumar, V., & Anwar, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121056 · Cited by 8
Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy
Eskandari, A., Leow, T. C., Rahman, M. B. A., & Oslan, S. N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01144-3 · Cited by 7
Metadata
- Authors
- Zhuang, X., Qi, Y., Wang, M., Yu, N., Nan, F., Zhang, H., Tian, M., Li, C., Lu, H., & Jin, N.
- Affiliations
- Academy of Military Medical Sciences (CN)
- Chinese Academy of Sciences (CN)
- Wenzhou University (CN)
- Yanbian University (CN)
- Jilin University (CN)
- Corresponding author
- Jin, Ningyi
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2020-03-10
- Volume
- 8
- Issue
- 1
- Pages
- 123
- ISSN
- 2076-393X (ISSN-L)
- PMC
- PMC7157730
- OpenAlex
- W3011203304
- Cited by
- 132
- References
- 28
- Citations by year
- 2026: 4 · 2025: 27 · 2024: 26 · 2023: 23 · 2022: 29 · 2021: 18 · 2020: 5
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vaccines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science and Technology Major Project of the Ministry of Science and Technology of China (2018ZX10102-001)
- Changchun Science and technology plan project (19SS016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- mRNA vaccines, influenza A (H1N1) virus, hemagglutinin, cationic lipid nanoparticles, 5' and 3' untranslated regions, in vitro transcription, gene delivery, intranasal immunization, humoral immune response, cell-mediated immunity, protective immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review